期刊文献+

放疗仍是Ⅲ期非小细胞肺癌重要的局部治疗手段 被引量:1

原文传递
导出
摘要 Ⅲ期非小细胞肺癌(NSCLC)的5年生存率为10% ~ 30%,如此大的生存率差异提示该期别存在不同预后的亚群.因此,有学者建议将Ⅲ期NSCLC分为以下6种:(1)Ⅲa-0期:指T3N1或T4N0~1.(2)Ⅲa-1期:术前和术中的分期检查未发现,而在术后标本的病理检查证实存在微小的同一侧纵隔淋巴结或隆突下淋巴结(N2)转移.(3)Ⅲa-2期:术中病理确诊单个N2转移.(4)Ⅲa-3期:术前分期检查(纵隔镜、穿刺或PET)证实为单个或多个N2淋巴结转移,但转移灶数目较少,淋巴结较小.(5)Ⅲa-4期:术前分期检查证实大块或固定N2淋巴结转移(通常标准为CT显示纵隔淋巴结短径>2 cm,伴有淋巴结胞膜外侵犯,有多组淋巴结转移和/或组内多个小淋巴结转移灶).(6)Ⅲb期:任何T伴N3.
作者 傅小龙
出处 《中国医师进修杂志》 2015年第5期324-327,共4页 Chinese Journal of Postgraduates of Medicine
  • 相关文献

参考文献8

  • 1Ripley RT, Rusch VW. Role of induction therapy: surgicalresection of non-small cell lung cancer after induction therapy [ J ]. Thorac Surg Clin, 2013,23 ( 3 ) : 273 -285.
  • 2Oh B, Kim KS, Kim YC, et al. A phase 11[ concurrent chemoradiotherapy trial with cisplatin and paclitaxel or docetaxel or gemcitabine in unresectable non-small cell lung cancer: KASLC 0401 [J]. Cancer Chemother Pharmacol, 2013,72 (6):1247- 1254.
  • 3Bayman N, Blackhall F, McCloskey P, et al. How can we optimise concurrent chemoradiotherapy for inoperable stage non-small cell lung cancer?[J]. Lung Cancer, 2014,83(2): 117-125.
  • 4P'o'ttgen C, Eberhardt W, Granpner B,et al. Accelerated hyperfractionated radiotherapy within trimodality therapy concepts for stage 111MB non-small cell lung cancer: markedly higher rate of pathologic complete remissions than with conventional fractionation [ J ]. Eur J Cancer, 2013,49 (9) : 2107-2115.
  • 5Horinouchi H, Sekine I, Sumi M, et al. Long-term results of concurrent ehemoradiotherapy using eisplatin and vinorelbine for stage I non-small-cell lung cancer [J]. Cancer Sci, 2013,104 ( 1 ) : 93-97.
  • 6Morgensztern D, Waqar S, Subramanian J,et al. Prognostic significance of tumor size in patients with stage 111 non-small-cell lung cancer: a surveillance,epidemiology, and end results (SEER) survey from 1998 to 2003 [J]. J Thorac Oncol, 2012,7 (10) : 1479-1484.
  • 7de Ruysscher D, Belderbos J, Reymen B, et al. State of the art radiation therapy for lung cancer 2012: a glimpse of the future[J]. Clin Lung Cancer, 2013,14(2) : 89-95.
  • 8Jeremic B, Videtic GM. Induction chemotherapy inevitably leads to inferior outcome in combined modality treatment for unresectable stage III non-small cell lung cancer [J]. J Thorac Oncol, 2012,7 (5) : 944-945.

同被引文献7

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部